<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938158</url>
  </required_header>
  <id_info>
    <org_study_id>108370</org_study_id>
    <nct_id>NCT00938158</nct_id>
  </id_info>
  <brief_title>A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.</brief_title>
  <official_title>An Adaptive Design Study for the Assessment of the Pharmacokinetics of Albiglutide in Subjects With Normal Renal Function and Subjects With Moderate-to-severe Renal Impairment and Hemodialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics and safety of a single
      subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with
      varying degrees of renal function, including subjects requiring hemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This adaptive design, non-randomized, open-label, staggered parallel group study evaluates
      the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in
      subjects with type 2 diabetes mellitus with varying degrees of renal function. During Stage
      1, a single dose of albiglutide will be administered to subjects with normal renal function
      and subjects with moderate-to-severe renal impairment not requiring hemodialysis. In addition
      to subjects with normal renal function and moderate renal impairment, Stage 2 of the study
      will also include cohorts of subjects requiring hemodialysis, subjects with severe renal
      impairment not requiring hemodialysis, and potentially subjects with mild renal impairment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2009</start_date>
  <completion_date type="Actual">April 12, 2011</completion_date>
  <primary_completion_date type="Actual">April 12, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to characterize the PK of albiglutide in subjects with type 2 diabetes and varying degrees of renal impairment, including subjects requiring hemodialysis, and in age, gender and BMI-matched subjects.</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of albiglutide in subjects with varying degrees of proteinuria</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of hemodialysis on the overall PK profile of albiglutide</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of a single dose of albiglutide in subjects with varying degrees of renal impairment and in age, gender and BMI-matched subjects with normal renal function</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Stage 1 normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 moderate/severe renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject with estimated GFR &gt;= 20 mL/min and less than 50 mL/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject with GFR greater than 80 mL/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject with estimated GFR &gt;= 30 mL/min and less than 50 mL/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 subjects requiring hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who require hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 severe renal impairment not requiring hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with GFR less than 30 mL/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with GFR &gt;= 50 mL/min and &lt;= 80 mL/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>albiglutide</intervention_name>
    <description>single dose of subcutaneously injected albiglutide</description>
    <arm_group_label>Stage 1 normal renal function</arm_group_label>
    <arm_group_label>Stage 2 normal renal function</arm_group_label>
    <arm_group_label>Stage 2 moderate renal impairment</arm_group_label>
    <arm_group_label>Stage 2 severe renal impairment not requiring hemodialysis</arm_group_label>
    <arm_group_label>Stage 1 moderate/severe renal function</arm_group_label>
    <arm_group_label>Stage 2 subjects requiring hemodialysis</arm_group_label>
    <arm_group_label>Stage 2 mild renal impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal renal function or renal impairment

          -  stable hemodialysis treatment for at least 3 months before screening and able to
             tolerate a hemodialysis treatment lasting 3-4 hours with blood flow rates of
             &gt;200mL/min (cohort 3 only)

          -  neither pregnant nor lactating

          -  HbA1c 6-10.5% inclusive

          -  females of childbearing potential must be practicing adequate contraception.

        Exclusion Criteria:

          -  inability to meet the PK objectives of the study

          -  history of hypoglycemia unawareness or severe hypoglycemia

          -  liver function tests greater than or equal to 2 times the ULN

          -  clinically significant cardiovascular and/or cerebrovascular disease

          -  positive test results for hepatitis B, hepatitis C, or HIV

          -  documented hypertension or hypotension at screening

          -  known hepatic or biliary abnormalities

          -  current use of sulfonylureas

          -  active history of tobacco use within 6 months before screening

          -  donation of blood in excess of 500mL within 56 days before albiglutide dosing

          -  receipt of any investigational drug within the 30days or 5 half lives, whichever is
             longer, before dosing

          -  previous or current receipt of exenatide or any other GLP-1 agonist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parktown</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <zip>07129</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/108370?search=study&amp;search_terms=108370#rs</url>
    <description>Results for study 108370 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>albiglutide</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>renal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>rGLP-1 protein</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>108370</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108370</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108370</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108370</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108370</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108370</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108370</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

